Recent Updates
Recently added Catalysts
CDNA Positive Sentiment

CareDx Announces Third Quarter 2026 Financial Results

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CareDx, Inc. reported strong financial results for Q3 2026, with revenue reaching $139 million, a 39% increase from the previous year. The company's Testing Services revenue surged to $119 million, reflecting a 65% year-over-year growth. Additionally, the volume of Testing Services rose by 51%, indicating robust demand.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased by 39% year-over-year.
  • Testing Services revenue rose by 65% year-over-year.
  • Testing Services volume grew by 51% year-over-year.

Full Press Release Details

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue of $139 million, an increase of 39% year-over-year Testing Services revenue of $119 million, an increase of 65% year-over-year Testing Services volume of approximately 75,900, an increase of 51% year-ove

Frequently Asked Questions

What were CareDx's total revenues for Q3 2026?

CareDx reported total revenues of $139 million for Q3 2026.

How much did Testing Services revenue increase?

Testing Services revenue increased by 65% year-over-year.

What was the volume of Testing Services in Q3 2026?

The volume of Testing Services was approximately 75,900.

What was the year-over-year growth for Testing Services volume?

Testing Services volume grew by 51% year-over-year.

ShareAdd on Google
Tags: CDNA CareDx financial results Q3 2026 revenue growth
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$374M liquidity · $0M/mo burn
Low dilution risk